智通财经APP获悉，康龙化成(03759)高开逾5%，截至发稿，涨5.43%，报19.61港元，成交额642.62万港元。
消息面上，3月11日，据康龙化成官微消息，公司与礼来公司共同宣布，达成关于首个申报注册的口服小分子GLP-1受体激动剂Orforglipron的生产合作协议。根据协议，礼来公司预期投资康龙化成2亿美元并支持其技术能力建设，未来将根据后续发展情况进一步扩大合作规模。此次与礼来公司就Orforglipron达成制剂商业化生产合作，是公司制剂CDMO的重要里程碑。
智通财经APP获悉，康龙化成(03759)高开逾5%，截至发稿，涨5.43%，报19.61港元，成交额642.62万港元。
消息面上，3月11日，据康龙化成官微消息，公司与礼来公司共同宣布，达成关于首个申报注册的口服小分子GLP-1受体激动剂Orforglipron的生产合作协议。根据协议，礼来公司预期投资康龙化成2亿美元并支持其技术能力建设，未来将根据后续发展情况进一步扩大合作规模。此次与礼来公司就Orforglipron达成制剂商业化生产合作，是公司制剂CDMO的重要里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.